摘要
目的:观察联合应用康复新、锡类散治疗溃疡性结肠炎的临床疗效。方法:收治溃疡性结肠炎患者72例,随机分成两组,每组36例,分别为美沙拉嗪联合康复新等治疗组(试验组)和美沙拉嗪口服组(对照组),疗程4周,记录两组临床症状缓解、结肠镜评分、疾病活动指数(DAI),应用SF-36量表进行生存质量评价及观察不良反应。结果:两组比较结肠镜评分、疾病活动指数(DAI)、生存质量评价(除躯体角色、情绪角色)、临床症状的缓解差异均有统计学意义(P<0.05)。结论:口服美沙拉嗪联合康复新、云南白药、锡类散治疗轻中度远段溃疡性结肠炎疗效显著,安全性高,症状缓解快。
Objective:To observe the clinical effect of combined with Kangfuxin,Xileisan retention enema in the treatment of ulcerative colitis.Methods:To admit 72 cases of patients with ulcerative colitis from January 2012 to 2013 December,were randomly divided into 2 groups,36 cases in each group,respectively,the mesalazine combined with Kangfuxin treatment group and oral mesalazine control group,treatment for 4 weeks,record clinical symptoms,colonoscopy score,disease activity index(DAI)of two groups of patients,the application of SF-36 scale was used for evaluation of the quality of life and observe the adverse reaction. Results:To compare colonoscopy score,disease activity index(DAI),the evaluation of quality of life(in addition to physical role, emotional role),relieve the clinical symptoms of two groups of patients,the differences were statistically significant(P<0.05). Conclusion:The curative effect of oral mesalazine combined with Kangfuxin,Xileisan retention enema in the treatment of mild to moderate distal ulcerative colitis is significantly,high security,relieve symptoms quickly.
